Clinical Trial

A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase Ib/II, open-label clinical study designed to evaluate the safety, tolerability, preliminary anti-tumor activity, recommended Phase 2 dose (RP2D), pharmacokinetic (PK) characteristics, and immunogenicity of DXC006 in combination with an immune checkpoint inhibitor (ICI) or platinum-based chemotherapy in patients with small cell lung cancer (SCLC).
Protocol Amendment History 1 change
minor Trial arms changed: 2 -> 3 2026-05-07
Trial Details
NCT Number NCT07559929
Lead Sponsor Hangzhou DAC Biotechnology Co., Ltd.
Conditions Small Cell Lung Cancer
Enrollment 200 participants
Start Date 2026-06-01
Primary Completion 2028-06-01 (estimated)
Study Completion 2030-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-29